Market Intelligence, Clinical Progress, and High-Purity Reagents for FGFR1-Driven Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FGFR1/CD331 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FGFR1 ECD-Fc / Kinase Domain Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View FGFR1/CD331 Products |
| Gene Delivery | FGFR1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View FGFR1/CD331 Products |
| Benchmark Ab | Anti-FGFR1 Recombinant Antibody (Sequence of Bemarituzumab analog). Sequence verified positive control for binding/blocking assays. | View FGFR1/CD331 Products |
| Validator | FGFR1 siRNA Set. For knockdown verification and specificity controls. | View FGFR1/CD331 Products |
| Related Target A | FGFR2. Paralog selectivity counter-screening; shared ligand biology and toxicity profiling. | View FGFR2 Products |
| Related Target B | FGFR3. Subfamily off-target safety evaluation; resistance bypass pathway analysis. | View FGFR3 Products |
| Related Target C | FGF2 (bFGF). Native ligand for activation and competition assays. | View FGF2 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno FGFR1 ECD ortholog proteins available with >95% purity, HEK293 expressed, native glycosylation. |
| Subfamily counter screening (FGFR2/3/4) | Homolog panel proteins (FGFR1/2/3/4 ECD & Kinase) strictly verified by mass spec for off-target liability. |
| Resistance mutation profiling | FGFR1 Kinase Domain WT & V561M Mutant recombinant proteins for differential binding and IC50 determination. |
| Internalization efficiency (ADC development) | High-purity ECD-Fc with native glycosylation preserves conformational epitopes for internalization assays. |
| Lack of Specificity Controls | Clinical Benchmark Antibody (Biosimilar) and validated siRNA included for assay standardization. |
| False Positives | Validated siRNA included for target-specificity checks. |
Live FGFR1/CD331 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FGFR1-targeted therapeutics is intensifying, with major players shifting focus from pan-FGFR inhibitors to highly selective FGFR1 antagonists and antibody-drug conjugates. As first-generation therapies demonstrate efficacy in FGFR1-amplified breast, lung, and gastric cancers, the next wave of R&D is targeting acquired resistance mutations (e.g., V561M) and combination strategies with EGFR/HER2 inhibitors and immune checkpoint inhibitors. Isoform-specific targeting aims to bypass broad toxicity such as hyperphosphatemia while maintaining efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Pan/Selective) | Janssen, Incyte, Taiho Oncology, QED Therapeutics | Urothelial carcinoma, Cholangiocarcinoma, Breast/NSCLC (FGFR1-amp) | Selectivity Assay (need mutant vs WT Kinase proteins) |
| Biologic (mAb/ADC) | Amgen, Five Prime, emerging biotechs | Gastric cancer, Breast cancer, Squamous NSCLC | Internalization Assay (need high-purity ECD-Fc); Binding Specificity (need homolog panel) |
| Combination Therapy | Various oncology pharma | Solid tumors | Cell-based Synergy Assay (need lentivirus stable lines) |
FGFR1/CD331 Molecular Profile
FGFR1 (CD331) is a receptor tyrosine kinase with three immunoglobulin-like C2-type domains in its extracellular region (Ig-like C2-type 1, 2, and 3; UniProt P11362). Key mutations include HH2 variants (uncertain significance, dbSNP:rs760884357; phenotype consistent with normosmic idiopathic hypogonadotropic hypogonadism, VAR_030968) and the missense variant rs17175750. These domains and mutations are critical for understanding ligand binding, receptor dimerization, and resistance mechanisms.